On March 16, 2011
InterMune’s New Lung-Disease Drug Doesn’t Deserve Its Hype
Analysts think InterMune’s lung-disease drug Esbriet can expect sales in excess of $1 billion annually. But it’s only sold in the EU, and there’s little proof the drug actually works.
No tags for this post.
0 Comments